Clinical trial

HR+/HER2- Advanced Breast Cancer and Endocrine Resistance

NCT03322215

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2017-10-24

PhasePHASE2

Study timeline

Study start (actual)2017-10-24Date precision: day

Registry last updated2024-03-08

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancer Metastaticunresolved

Interventions

PalbociclibDRUG · verified · RxNorm: palbociclib

FulvestrantDRUG · verified · RxNorm: fulvestrant

CapecitabineDRUG · verified · RxNorm: capecitabine

Sponsors & collaborators

Theodoros Foukakislead sponsor

Mapped research locations

StockholmSweden2 GlasgowUnited Kingdom1 GothenburgSweden1 UppsalaSweden1 EdinburghUnited Kingdom1 MalmöSweden1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03322215 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.